跳至主要内容
临床试验/EUCTR2017-002959-29-NL
EUCTR2017-002959-29-NL进行中(未招募)1 期

Comparison of the beta cell mass during and shortly after the honeymoon phase of type 1 diabetes using Ga-68-exendin PET - GLP1-honeymoon

Radboud university medical center0 个研究点目标入组 18 人开始时间: 2017年11月13日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Age =16 years
  • -Subject is diagnosed with type 1 diabetes (T1D)
  • -Presence of anti-GAD (glutamic acid decarboxylase)
  • - Subject is in the honeymoon phase of T1D: IDAA1c <9
  • -17= BMI =30 kg/m^2
  • -Ability to sign informed consent
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 18
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 12
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Previous treatment (within 6 months) with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl-Peptidase lV
  • - Liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of the normal range
  • - Renal disease defined as MDRD <40 ml/min/1.73 m^2
  • - Pregnancy or the wish to become pregnant within 6 months after the study
  • - Breastfeeding
  • - BMI <17 kg/m^2 or BMI >30 kg/m^2
  • - Age <16 years
  • - When the end of the honeymoon phase (IDAA1c =9) is not observed within 11 to 13 months after the inclusion of the subject
  • - lnability to sign informed consent

研究者

相似试验